LLY
Eli Lilly and Company
LLY has the edge over PROK overall, supported by stronger fundamentals and lower modeled downside.
PROK
ProKidney Corp.
PROK trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PROK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
PROK's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PROK PE Valuation
PROK has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PROK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PROK's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PROK on earnings quality, reporting a profit while its opponent remains loss making.
PROK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.62 | -$0.07 |
| Q2 2026 | -$0.57 | $0.00 |
| Q1 2026 | -$0.55 | +$0.05 |
| Q4 2025 | -$0.52 | +$0.11 |
| Q3 2025 | -$0.55 | +$0.01 |
| Q2 2025 | -$0.57 | +$0.03 |
| Q1 2025 | -$0.60 | -$0.02 |
PROK lost $0.62 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PROK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PROK on profitability, with a higher operating margin.
PROK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $174K | -20% |
| Q2 2026 | $150K | -32% |
| Q1 2026 | $226K | -1.7% |
| Q4 2025 | $225K | +196% |
PROK's revenue is growing: $174,000 last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30895% | -13136 points |
| Q2 2026 | -32249% | -14281 points |
| Q1 2026 | -19882% | -1887 points |
| Q4 2025 | -20165% | +47692 points |
| Q3 2025 | -17760% | N/A |
| Q2 2025 | -17968% | N/A |
| Q1 2025 | -17995% | N/A |
| Q4 2024 | -67857% | N/A |
PROK's operating margin was −30895% last quarter, down 13135 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PROK on cash generation, producing positive trailing cash flow while its opponent burns cash.
PROK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.9M | -$8.1M |
| Q2 2026 | -$44.2M | -$9.7M |
| Q1 2026 | -$45.5M | -$14.7M |
| Q4 2025 | -$38.3M | +$11.4M |
| Q3 2025 | -$31.8M | -$148K |
| Q2 2025 | -$34.5M | +$4.4M |
| Q1 2025 | -$30.7M | +$4.9M |
| Q4 2024 | -$49.7M | -$22.7M |
PROK has burned cash in almost every quarter: −$168M over the past year, against −$147M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PROK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PROK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +62% | +116M shares |
| 1 year | +124% | +167M shares |
| 3 years | +391% | +241M shares |
PROK has 302M diluted shares, up 124% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PROK Net Leverage
PROK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PROK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.2 | Neutral |
| Stochastic | 15.2 | Oversold |
PROK's weekly RSI is 38 (neutral) and its Stochastic is 15 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PROK PE vs Healthcare Sector
PROK has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PROK on trend strength, trading above more of its moving averages.
PROK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.42 | 19% below |
| 20 week MA | $1.60 | 28% below |
| 50 week MA | $1.86 | 38% below |
| 100 week MA | $1.83 | 37% below |
| 200 week MA | $3.48 | 67% below |
PROK is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PROK on returns for 2026, with the stronger performance.
PROK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $9.86 | -1.9% |
| 2022 | $9.86 | $6.53 | -34% |
| 2023 | $6.53 | $1.78 | -73% |
| 2024 | $1.78 | $1.70 | -4.5% |
| 2025 | $1.70 | $2.53 | +49% |
| 2026 YTD | $2.53 | $1.15 | -55% |
PROK has finished lower in four of the last five years. It's down 55% so far in 2026.